Halozyme Therapeutics (HALO) to Release Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is expected to be announcing its Investor update results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $1.92 per share for the quarter. Interested persons can find conference call details on the company’s upcoming Investor update earning report page for the latest details on the call scheduled for Wednesday, January 28, 2026 at 8:30 AM ET.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $80.48 on Tuesday. Halozyme Therapeutics has a 12-month low of $47.50 and a 12-month high of $82.22. The firm has a market cap of $9.46 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 0.34 and a beta of 0.97. The company’s 50-day moving average is $69.68 and its two-hundred day moving average is $69.39. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HALO shares. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Morgan Stanley reduced their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and an average target price of $78.80.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the transaction, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. This trade represents a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at $53,947,690.28. The trade was a 2.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 49,398 shares of company stock worth $3,650,592 in the last quarter. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC grew its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Wexford Capital LP purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $70,000. Employees Retirement System of Texas lifted its holdings in shares of Halozyme Therapeutics by 64.6% during the 3rd quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 427 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at $195,000. 97.79% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.